Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan - Poll - MDSpire

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan

  • By

  • Hideyo Kasai

  • Taro Yasumoto

  • Shota Kosuge

  • Ayako Osanai

  • Keita Mizuma

  • Akinori Futamura

  • Takeshi Kuroda

  • Kenjiro Ono

  • Hidetomo Murakami

  • May 13, 2026

  • 0 min

Share

Original Source(s)

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan

  • by Hideyo Kasai, Taro Yasumoto, Shota Kosuge, Ayako Osanai, Keita Mizuma, Akinori Futamura, Takeshi Kuroda, Kenjiro Ono, Hidetomo Murakami

  • May 13, 2026

Related Content

Development and validation of a digital tool to aid in migraine diagnosis

Migraine with comorbid fibromyalgia: psychological burden and impact on frequency and severity of migraine attacks

Objective oculomotor, vestibular, reaction time, and cognitive signatures of vestibular migraine